JAN 31·Shreveport TimesMed
NanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza Wave - NV-387 is Effective Against H3N2
NanoViricides highlights the urgent need for broad-spectrum antivirals, especially during the current severe influenza season dominated by the H3N2 variant, against which seasonal vaccines are less effective. The company's drug candidate, NV-387, is presented as a promising solution due to its broad-spectrum efficacy against influenza, RSV, and Coronaviruses, operating through a mechanism that viruses are unlikely to escape. NV-387 is currently in Phase II clinical trials and is being positioned as a potential first-line empiric therapy for respiratory viral infections.